NCT04824872View on ClinicalTrials.gov

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2023

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
HypoglycemiaGlucose Metabolism Disorders
Interventions
DRUG

Dasiglucagon

dasiglucagon SC, low dose

DRUG

Dasiglucagon

dasiglucagon SC, high dose

DRUG

Placebo

placebo for dasiglucagon

Sponsors

Lead Sponsor

Zealand Pharma
All Listed Sponsors
lead

Zealand Pharma

INDUSTRY

NCT04824872 - Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults | Biotech Hunter | Biotech Hunter